KCNK17 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL498641	1.00	1/20
SCHEMBL4231221	0.85	1/20
SCHEMBL12434336	0.84	1/20
SCHEMBL12434391	0.83	1/20
SCHEMBL4231667	0.79	1/20
SCHEMBL4234451	0.79	1/20
SCHEMBL12434396	0.79	1/20
SCHEMBL4234905	0.78	1/20
SCHEMBL12434045	0.78	1/20
SCHEMBL726080	0.77	1/20
SCHEMBL13789620	0.74	1/20
SCHEMBL12434450	0.73	1/20
SCHEMBL13789610	0.71	1/20
SCHEMBL12434333	0.69	1/20
SCHEMBL12434042	0.68	1/20
SCHEMBL12434334	0.68	1/20
SCHEMBL12434091	0.67	1/20
SCHEMBL13789469	0.67	1/20
SCHEMBL12434454	0.67	1/20
SCHEMBL2634370	0.66	1/20

Clinical trials — most relevant to KCNK17 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study	PHASE4	COMPLETED
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes	PHASE4	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Sandostatine® LP and Hyperinsulinism	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric Participants With KCNT1-related Epilepsy	PHASE2	RECRUITING
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors	PHASE1	UNKNOWN
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment	PHASE1	RECRUITING
Peripheral KV7 Activation for Pain Relief	EARLY_PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk	nan	COMPLETED
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
Comparing Direct vs Indirect Methods for Cascade Screening	nan	RECRUITING
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients	nan	UNKNOWN
Gene Study for Infantile Onset Diabetes	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNK17 binder may also engage these)

Protein	Name	Similarity
Q96T55	—	0.986	Q96T55 →
O88454	—	0.981	O88454 →
G3V8V5	—	0.980	G3V8V5 →
G5E845	—	0.979	G5E845 →
Q9Y2U2	—	0.967	Q9Y2U2 →
Q9Z2T1	—	0.965	Q9Z2T1 →
KCNK4	Potassium channel subfamily K member 4	0.963	landscape →
Q8R1P5	—	0.961	Q8R1P5 →
Q8VCF5	—	0.959	Q8VCF5 →
Q8TDN1	—	0.958	Q8TDN1 →
Q9H427	—	0.957	Q9H427 →
Q9HBX8	—	0.957	Q9HBX8 →
Q9ERS0	—	0.956	Q9ERS0 →
O89109	—	0.956	O89109 →
Q6Q1P3	—	0.956	Q6Q1P3 →
KCNK13	Potassium channel subfamily K member 13	0.956	landscape →
E2RD63	—	0.955	E2RD63 →
A6NH21	—	0.955	A6NH21 →
P08923	—	0.955	P08923 →
Q3UVD5	—	0.955	Q3UVD5 →
Q60850	—	0.954	Q60850 →
Q8IU68	—	0.954	Q8IU68 →
Q9H6D3	—	0.954	Q9H6D3 →
KCNN4	Intermediate conductance calcium-activated potassium channel protein 4	0.954	landscape →
A7MBM2	—	0.954	A7MBM2 →
Q0P5A0	—	0.953	Q0P5A0 →
Q49LS0	—	0.953	Q49LS0 →
Q49LS3	—	0.953	Q49LS3 →
Q5GH66	—	0.953	Q5GH66 →
Q5GH72	—	0.953	Q5GH72 →